Biogen Newsroom

Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker

BenzingaAug 28 04:21 ET

Eli Lilly and Co's Alzheimer's drug, Donanemab, may be rejected by the United Kingdom's healthcare regulatory institutions.

After the regulatory institutions in the United Kingdom refused to approve Leqembi, the Alzheimer's disease drug owned by Baijian, for use in the National Health Service (NHS), there have been reports that Donanemab, another Alzheimer's disease drug owned by Eli Lilly and Co, will face the same fate.

Zhitong FinanceAug 25 22:15 ET

Eli Lilly Alzheimer's Drug Set to Face Same Fate as Biogen's in U.K.: Report

Seeking AlphaAug 24 13:16 ET

Biopharmaceuticals Global Business Report 2024 With Focus on 200+ Select Players Including Abbott, Amgen, Biogen, Eli Lilly and Co, F. Hoffmann-La Roche, J&J, Merck, Novo Nordisk, Pfizer, Sanofi

Yahoo FinanceAug 23 07:20 ET

Eisai and Biogen's Alzheimer's Drug Leqembi Receives MHRA Approval in Great Britain

MT NewswiresAug 22 22:11 ET

Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement

BenzingaAug 22 13:45 ET

Why Biogen Inc. (BIIB) Is a Top Value Stock for the Long-Term

Yahoo FinanceAug 22 09:40 ET

Sector Update: Health Care Stocks Flat to Higher Premarket Thursday

MT NewswiresAug 22 09:18 ET

Biogen, Eisai's Alzheimer's Drug Deemed Too Costly for UK National Health Service

MT NewswiresAug 22 07:57 ET

Biogen (BIIB.US) and Eisai (ESALF.US) subsidiary's Alzheimer's disease drug Leqembi has received marketing authorization in the United Kingdom.

According to the Zhītōng Finance APP, Biijian (BIIB.US) and its Japanese partner Wèicái (ESALF.US) announced on Thursday that their groundbreaking Alzheimer's disease treatment drug Leqembi (lecanemab) has obtained marketing authorization in the United Kingdom.

Zhitong FinanceAug 22 07:30 ET

Eisai, Biogen Score U.K. Nod for Alzheimer's Drug -- Market Talk

WSJAug 22 05:59 ET

Eisai and Biogen's Alzheimer's Drug Leqembi Receives First European Approval in Great Britain

BenzingaAug 22 05:13 ET

Express News | Biogen: Eisai Working With Nice, SMC and Nhs to Make This Medicine Available to Eligible People Living With Early Ad as Soon as Possible

ReutersAug 22 05:12 ET

Express News | UK's Nice: Benefits of Alzheimer’s Treatment Lecanemab Are Too Small to Justify Cost to the Nhs

ReutersAug 22 05:00 ET

Express News | UK's Mhra: Lecanemab Licensed for Adult Patients in Early Stages of Alzheimer’s Disease

ReutersAug 22 05:00 ET

Express News | UK's Mhra: Together With Conditions of Licence Approval, Appropriate Regulatory Standards for Lecanemab Have Been Met

ReutersAug 22 05:00 ET

Express News | UK's Nice: Issued Draft Guidance for Consultation Not Recommending Lecanemab for Use on Nhs as It Is Not Cost Effective Use of Limited Nhs Funding

ReutersAug 22 05:00 ET

Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Reata PharmaceuticalsAug 22 00:00 ET

BioCentury to Host Grand Rounds in Nashville: A Premier Gathering of Drug Development Thought Leaders at the Interface of Academia and Industry

BusinesswireAug 20 15:37 ET

Is Wall Street Bullish or Bearish on Biogen Stock?

BarchartAug 20 10:58 ET